JTO & JTO CRR

🎉 As we celebrate 20 years of JTO, we recognize the global community that has helped make the journal a leading voice in thoracic oncology research.

In this anniversary video, JTO Editor-in-Chief Dr. Alex Adjei reflects on the dedication of the journal’s associate editors, editorial board, reviewers, and IASLC members who have contributed to its success over the past two decades.

Hear Dr. Adjei share how this global collaboration continues to drive JTO’s impact and advance lung cancer research worldwide.

#JTO20 #IASLC #LungCancer #ThoracicOncology

Thank you to Graham Warren for ten years of helping JTO serve as a trusted resource for the global thoracic oncology community! #JTO20

Patients with pulmonary carcinoid have a well-differentiated, though rare, tumor. But not much is known about the disease’s response to DLL3-targeted bispecific T-cell engager #tarlatamab. @JessieStuart316 et al. analyzed the response in 11 patients at Memorial Sloan Kettering Cancer Center and found that #tarlatamab is a promising treatment option for patients with PC.

Read more here: bit.ly/4suaCsN

#LungCancerResearch #JTO

What does 20 years of JTO mean to those who have helped shape its success?

Associate Editor William Travis shares his reflections as we continue celebrating the journal's legacy and contributions to thoracic oncology.

#JTO20 #IASLC

Here's to a year of dedication, leadership, and service! Thank you, Suzanne Dahlberg, for your contributions to JTO! #JTO20